Document is current
Any future updates will be listed below
-
Authors
Takemon, Yuka
Pleasance, Erin D.
Gagliardi, Alessia
Hughes, Christopher S.
Csizmok, Veronika
Wee, Kathleen
Trinh, Diane L.
Huff, Ryan D.
Mungall, Andrew J.
Moore, Richard A.
Chuah, Eric
Mungall, Karen L.
Lewis, Eleanor
Nelson, Jessica
Lim, Howard J.
Renouf, Daniel J.
Jones, Steven JM.
Laskin, Janessa
Marra, Marco A.
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 29 October 2024
First Online: 22 November 2024
Declarations
:
: This study was approved by the UBC BC Cancer Research Ethics Board (H19-03010 and H20-02317). The work involving POG program patients (registered under clinical trial number NCT02155621) was approved by the University of British Columbia–BC Cancer Research Ethics Board (H12-00137, H14-00681, H20-02317) and conducted in accordance with the principles of the Helsinki Declaration. All patients in this study gave informed written consent to participate and were enrolled into POG as described previously, between July 7th, 2012 and January 13th, 2023 [, , ].
: Research related to patients enrolled in the POG program conformed with the principles of the Helsinki Declaration.
: The authors declare no competing interests.
